Article
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
Journal of viral hepatitis - 1 Apr 2017
Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld J J, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson I M, Dumas E O, King M, Sulkowski M
Abstract excerpt
High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.